Country: Malta
Language: English
Source: Medicines Authority
POTASSIUM IODIDE
G.L. Pharma GmbH Schlossplatz 1, 8502 Lannach, Austria
V03AB21
POTASSIUM IODIDE 65 mg
TABLET
POTASSIUM IODIDE 65 mg
OTC
ALL OTHER THERAPEUTIC PRODUCTS
Authorised
2014-02-17
PACKAGE LEAFLET: INFORMATION FOR THE USER POTASSIUM IODIDE G.L. PHARMA 65 MG TABLETS Potassium iodide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your pharmacist has told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Potassium iodide G.L. Pharma is and what it is used for 2. What you need to know before you take Potassium iodide G.L. Pharma 3. How to take Potassium iodide G.L. Pharma 4. Possible side effects 5. How to store Potassium iodide G.L. Pharma 6. Contents of the pack and other information 1. WHAT POTASSIUM IODIDE G.L. PHARMA IS AND WHAT IT IS USED FOR Potassium iodide is used in cases of nuclear accidents or nuclear reactor accidents to prevent the uptake of radioactive iodine by the thyroid. In the event of nuclear reactor accidents, there may be an emission of radioactive iodine. In case of contamination, the radioactive iodine is taken up by the thyroid. The uptake of radioactive iodine by the thyroid is prevented by the intake of non-radioactive iodine (e.g. in the form of potassium iodide) before or during the contamination. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE POTASSIUM IODIDE G.L. PHARMA DO NOT TAKE POTASSIUM IODIDE G.L. PHARMA • if you are allergic to potassium iodide or any of the other ingredients of this medicine (listed in section 6). • if you have an autoimmune disease involving itching and blisters of your skin (dermatitis herpetiformis van Dühring). • if you have an overactive thyroid producing too much of thyroid hormones (hyperthyreosis). • if you have a certain disorder of your blood vessel walls (hypocomplementaemic vasculitis). WARNINGS AND PRECAUTIONS Talk to your doctor or p Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Potassium iodide G.L. Pharma 65 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains _ _ 65 mg potassium iodide, equivalent to 50 mg iodine. Excipient with known effect: 1 tablet contains 80 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Diameter: about 8.3 mm Thickness: 3.2 – 3.8 mm White to brown-white, round, curved tablet with a pressure-sensitive cross break line on the inner side and notches on the outer side. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For use after nuclear accidents with release of radioactive iodine isotopes to prevent the uptake of radioactive iodine in the thyroid after intake or inhalation of this substance. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Iodine tablets may only be taken after explicit appeal by the authority, for example via radio or television. Timing of administration It is recommended to use the tablets as soon as possible and preferably within 2 hours after the expected onset of exposure. However, an administration up to 8 hours after the estimated onset of exposure is still useful. Posology Adults and children above 12 years: 100 mg iodine (2 tablets) Children from 3 to 12 years: 50 mg iodine (1 tablet) Children from 1 month to 3 years: 25 mg iodine (½ tablet) Newborns and babies younger than a month: 12.5 mg iodine (¼ tablet) Pregnant and breast-feeding women (all ages): 100 mg iodine (2 tablets) Duration of administration A single administration is usually sufficient. If the release of radioactive iodine continues (> 24 hours), with repeated exposure, intake of contaminated food or drinking water and if evacuation is not possible, a repeated administration may be necessary. _Special populations _ Neonates, pregnant and breast-feeding women and older adults (> 60 years) should not receive more than one dose (see section 4.6). Neonates and older people (> 60 years) are a Read the complete document